Sanofi Says Insulin U300 Met Study Goals
NEW YORK (AP) — Sanofi said Tuesday that its insulin U300 met its primary goals in a series of clinical trials, but some results were mixed.
In one study, patients treated with U300 were less likely to have low nighttime blood sugar levels compared with Lantus, an older insulin sold by Sanofi. In another trial, called EDITION III, U300 wasn't significantly better than Lantus at reducing occurrences of low blood sugar at night.
But in yet another study, which the company reported on in June, U300 worked better than Lantus at reducing those events.
U.S.-traded shares fell $1.30, or 2.5 percent, to to close at $50.70.
U300 is intended to be a longer-lasting version of Lantus that can be administered in lower doses. The company plans to file for marketing approval in the U.S. and European Union in the first half of 2014.
Sanofi reported $6.55 billion in Lantus revenue in 2012.
Jefferies & Co. analyst Jeffrey Holford said U300 could be on the market in the first half of 2015, and the mixed data from EDITION III shouldn't hurt sales.